Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
Spotlight Series: HIV Stigma and Discrimination
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Tesamorelin Approved for Lipodystrophy

By Liz Highleyman
 From San Francisco AIDS Foundation

Summer/Fall 2010

In November, the FDA approved tesamorelin (Egrifta; formerly known as TH9507) for treatment of a type of lipodystrophy in HIV positive people taking antiretroviral therapy. Tesamorelin is a synthetic growth hormone-releasing factor that stimulates the pituitary gland to secrete more human growth hormone.

Approval was based on clinical trials showing that daily tesamorelin injections significantly decreased visceral abdominal fat and lowered total cholesterol levels. The drug was generally well-tolerated and caused fewer side effects than growth hormone itself. For more information, see "Drug Watch: Tesamorelin Update," in this issue.

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.




  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF
This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
 
See Also
An HIVer's Guide to Metabolic Complications
More on Egrifta (Tesamorelin)
No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement